Patent US3292627A successfully refreshed from Google Patents.
US4001433A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Quaternary ammonium compounds useful as antifibrillatory agent
Assignee: SmithKline Beecham Corp
•
Filing: 1974-04-01
•
Granted: 1977-01-04
•
Expires: 1994-04-01
Abstract
Abstract Compounds containing the N-m-methoxybenzyl-N,N-dimethyl-N-2-hydroxyethylammonium cation and non-toxic salts of the N-m-methoxybenzyl-N,N-dimethyl-N-ethylammonium cation. The compounds have antiarrhythmic properties, and are useful specifically as antifibrillatory agents.
Inventors
- 👤 Robert Arthur Maxwell
- 👤 Frederick Charles Copp
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/14
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
53 words
A method for the treatment or suppression of cardiac arrhythmias in a mammal which has had cardiac arrhythmias and which is in need of said treatment or suppression comprising the administration to said mammal of a non-toxic, effective anti-arrhythmic treatment or suppression amount of a pharmaceutically acceptable non-toxic salt of the N-m-methoxybenzyl-N,N-dimethyl-N-ethyl-ammonium cation.
Claim 2
Independent Claim
53 words
A method for the treatment or suppression of cardiac arrhythmias in a mammal which has had cardiac arrhythmias and which is in need of said treatment or suppression comprising the administration to said mammal of a non-toxic, effective anti-arrhythmic treatment or suppression amount of a pharmaceutically acceptable non-toxic salt of the N-m-methoxybenzyl-N,N-dimethyl-N-ethyl-ammonium cation.
Claim 3
Dependent Claim
12 words
The method of claim 1 in which the arrhythmias are ventricular arrhythmias.
Claim 4
Dependent Claim
12 words
The method of claim 1 in which the arrhythmias are atrial arrhythmias.
Claim 5
Dependent Claim
26 words
The method of claim 1 in which the arrhythmias are atrial or ventricular arrhythmias and the amount is 1 to 10 mg. based on the cation.
Claim 6
Dependent Claim
12 words
The method of claim 4 in which the mammal is a human.
Claim 7
Dependent Claim
14 words
The method of claim 5 in which the salt is parenterally or orally administered.
Claim 8
Dependent Claim
12 words
The method of claim 1 in which the mammal is a human.
Claim 9
Dependent Claim
14 words
The method of claim 1 in which the salt is parenterally or orally administered.
Claim 10
Dependent Claim
20 words
The method of claim 1 in which the salt is parenterally or orally administered and the mammal is a human.
Claim 11
Dependent Claim
16 words
The method of claim 1 in which the salt is a chloride, sulphate or sulphonate salt.
Claim 12
Independent Claim
55 words
A method for the treatment or suppression of cardiac arrhythmias in a mammal which has had a cardiac arrhythmias and which is in need of said treatment or suppression comprising the administration to said mammal of a non-toxic, effective anti-arrhythmic treatment of suppression amount of a pharmaceutically acceptable non-toxic salt of the N-m-methoxybenzyl-N,N-dimethyl N-2-hydroxyethylammonium cation.
Claim 13
Independent Claim
55 words
A method for the treatment or suppression of cardiac arrhythmias in a mammal which has had a cardiac arrhythmias and which is in need of said treatment or suppression comprising the administration to said mammal of a non-toxic, effective anti-arrhythmic treatment of suppression amount of a pharmaceutically acceptable non-toxic salt of the N-m-methoxybenzyl-N,N-dimethyl N-2-hydroxyethylammonium cation.
Claim 14
Dependent Claim
12 words
The method of claim 11 in which the arrhythmias are ventricular arrhythmias.
Claim 15
Dependent Claim
12 words
The method of claim 11 in which the arrhythmias are atrial arrhythmias.
Claim 16
Dependent Claim
26 words
The method of claim 11 in which the arrhythmias are atrial or ventricular arrhythmias and the amount is 1 to 10 mg. based on the cation.
Claim 17
Dependent Claim
12 words
The method of claim 14 in which the mammal is a human.
Claim 18
Dependent Claim
14 words
The method of claim 15 in which the salt is parenterally or orally administered.
Claim 19
Dependent Claim
12 words
The method of claim 11 in which the mammal is a human.
Claim 20
Dependent Claim
14 words
The method of claim 11 in which the salt is parenterally or orally administered.
Claim 21
Dependent Claim
20 words
The method of claim 11 in which the salt is parenterally or orally administered and the mammal is a human.
Claim 22
Dependent Claim
16 words
The method of claim 11 in which the salt is a chloride, sulphate or sulphonate salt.
Claim 23
Dependent Claim
42 words
A pharmaceutical composition in dosage form adapted for administration to treat or suppress cardiac arrhythmias comprising per dosage unit an effective cardiac arrhythmia treatment or suppression amount of a pharmaceutically-acceptable non-toxic salt of the N-m-methoxybenzyl-N,N-dimethyl-N-ethylammonium cation and a pharmaceutically acceptable carrier therefore.
Claim 24
Dependent Claim
42 words
A pharmaceutical composition in dosage form adapted for administration to treat or suppress cardiac arrhythmias comprising per dosage unit an effective cardiac arrhythmia treatment or suppression amount of a pharmaceutically-acceptable non-toxic salt of the N-m-methoxybenzyl-N,N-dimethyl-N-ethylammonium cation and a pharmaceutically acceptable carrier therefore.
Claim 25
Dependent Claim
12 words
The composition of claim 21 in a form for an oral administration.
Claim 26
Dependent Claim
11 words
The composition of claim 21 in a form for parenteral administration.
Claim 27
Dependent Claim
11 words
The composition of claim 21 in the form of a tablet.
Claim 28
Dependent Claim
12 words
The composition of claim 21 in the form of an injectible solution.
Claim 29
Dependent Claim
16 words
The composition of claim 21 in which the salt is a chloride, sulphate or sulphonate salt.
Claim 30
Dependent Claim
16 words
The composition of claim 21 in which the amount is 100 to 600 mg. of cation.
References Cited (Backward Citations)
GB912949A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-01-04 | 1980-07-05 | 1981-01-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-01-04 | 1984-07-05 | 1985-01-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-01-04 | 1988-07-05 | 1989-01-04 | $7700.00 | Window Closed / Lapsed |